To target metastatic melanoma, inhibitors of the RAF/MEK pathway have shown partial clinical success,7, 8 but their effectiveness is hampered due to development of resistance.27 To improve the prognosis for melanoma patients, efforts now focus on either intermittent treatment schedules for existing drugs,28 development of new RAF/MEK inhibitors,29, 30 sequential treatment of resistant tumors31 or combination therapies.27, 32 Much less attention has been devoted to targeting proteins that function downstream of MEK and promote cell survival or cell cycle progression. This evidence concerns the gene MAP2K7 and melanoma.